Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;34(2):e14833.
doi: 10.1111/dth.14833. Epub 2021 Feb 21.

Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review

Ayman Grada  1 , Steven R Feldman  2 , Nicola Luigi Bragazzi  3 , Giovanni Damiani  4   5   6
Affiliations

Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review

Ayman Grada et al. Dermatol Ther. 2021 Mar.

Abstract

Patients' perspectives on actinic keratosis treatments may have an impact on treatment adherence and, therefore, therapeutic outcomes. We performed a systematic review to assess patients' perspectives of topical, field-directed treatments for actinic keratoses. A literature search was conducted, and 14 studies were identified encompassing 4433 patients. Only four studies were focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a validated patient-reported outcomes (PRO) instrument specifically developed for actinic keratosis. In general, treatment adherence and patient satisfaction were better with shorter-duration treatment regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well-tolerated, short-duration topical treatment for actinic keratosis.

Keywords: actinic keratosis; adherence; compliance; patient-reported outcomes; safety; systematic review; tolerability; topical.

PubMed Disclaimer

Conflict of interest statement

Ayman Grada, MD, MS is an employee of Almirall LLC. Steve Feldman, MD, PhD received research, speaking and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Helsinn, Arena, Forte, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He consults for others through Guidepoint Global, Gerson Lehrman and other consulting organizations. He is founder and majority owner of www.DrScore.com. He is also a founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment.

Figures

FIGURE 1
FIGURE 1
PRISMA flow diagram of the study
See this image and copyright information in PMC

References

    1. Gilchrest BA. Actinic keratoses: reconciling the biology of field cancerization with treatment paradigms. J Invest Dermatol. 2020;S0022‐202X(20)32068‐6. [online ahead of print]. - PubMed
    1. Yaldiz M. Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Medicine (Baltimore). 2019;98(28):e16465. - PMC - PubMed
    1. Dziunycz PJ, Schuller E, Hofbauer GFL. Prevalence of actinic keratosis in patients attending general practitioners in Switzerland. Dermatology. 2018;234(5–6):214‐219. - PubMed
    1. Velter C. Épidémiologie des kératoses actiniques: epidemiology of actinic keratosis. Ann Dermatol Venereol. 2019;146(Suppl 2):IIS3‐IIS9. - PubMed
    1. Johnston BC, Patrick DL, Devji T, et al. Chapter 18: Patient‐reported outcomes. In: Higgins JPT, Thomas J, Chandler J, et al., (eds.). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley; 2019: 479‐492.

Publication types